Is event-driven PrEP dosing for HIV as effective as daily dosing?
| Autor: | Zachary Lally-Montgomery, Jon O. Neher, Sarah Safranek, Tory Olsen, Gary Kelsberg |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Dose-Response Relationship Drug business.industry Human immunodeficiency virus (HIV) MEDLINE HIV Infections medicine.disease_cause Placebo law.invention Randomized controlled trial law Internal medicine Cohort medicine Humans Pre-Exposure Prophylaxis Dosing business Prospective cohort study Event (probability theory) |
| Zdroj: | The Journal of family practice. 70(5) |
| ISSN: | 1533-7294 |
| Popis: | PROBABLY, although there are no head-to-head trials comparing the 2 dosing regimens. Event-driven pre-exposure prophylaxis (PrEP) dosing reduces HIV conversion by 86% compared to placebo (strength of recommendation [SOR]: B, large randomized controlled trial [RCT]). Daily PrEP reduces HIV conversion by 44% to 86% (SOR: B, based on open-label RCTs).Event-driven PrEP regimens may be associated with lower adherence when compared with daily PrEP regimens (average of 70% for event-driven PrEP vs average of 92% for daily PrEP) (SOR: B, based on open-label and cohort trials). Event-driven PrEP regimens have lower medication costs, and they are associated with no difference in the rate of sexually transmitted infections (STIs) (SOR: B, based on prospective cohort studies). Patients may prefer them to daily regimens (75% choose event driven PrEP vs 25% choose daily PrEP) (SOR: BB, based on the preponderance of prospective cohort studies with conflicting results). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|